Journal Article DKFZ-2019-00541

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png
Carbon irradiation overcomes glioma radioresistance by eradicating stem cells and forming an antiangiogenic and immunopermissive niche.

 ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;

2019
JCI Insight Ann Arbor, Michigan

JCI insight 4(2), e123837 () [10.1172/jci.insight.123837]
 GO

This record in other databases:  

Please use a persistent id in citations: doi:

Abstract: Tumor radioresistance leading to local therapy failure remains a major obstacle for successful treatment of high-grade glioma. We hypothesized that distinct radiobiological features of particle therapy with carbon ions may circumvent glioma radioresistance. We demonstrate that carbon irradiation (CIR) efficiently eradicates radioresistant patient-derived glioma stem cells (GSCs), leading to growth inhibition and prolonged survival. The impact of CIR at the tumor-stroma interface was further investigated in 2 syngeneic mouse and 2 orthotopic GSC xenograft models. Intriguingly, tumor regressions and long-term local controls were observed at doses greater than or equal to 15-Gy CIR. Fractionated CIR further prolonged survival. The enhanced relative biological effectiveness of CIR in vivo was attributed to its potent antiangiogenic effects and eradication of radioresistant hypoxic tumor cells. Blockade of the HIF1-α/stromal cell-derived factor 1/CXCR4 axis by CIR reduced the recruitment of microglia and myeloid-derived suppressor cells (CD11b+Gr1+). Consequently, CIR abrogated M2-like immune polarization and enhanced the influx of CD8+ cells, generating an immunopermissive niche. We report that radiotherapy with carbon ions could surmount several central glioma resistance mechanisms by eradicating hypoxic and stem cell-like tumor cells, as well as modulating the glioma niche toward an antiangiogenic and less immunosuppressive state. Conclusively, potentially novel rationales for CIR in conquering glioma radioresistance are provided.

Classification:

Contributing Institute(s):
  1. Translationale Radioonkologie (E210)
  2. KKE Neuroonkologie (B320)
  3. KKE Nuklearmedizin (E060)
  4. KKE Strahlentherapie (E050)
  5. DKTK Heidelberg (L101)
Research Program(s):
  1. 315 - Imaging and radiooncology (POF3-315) (POF3-315)

Appears in the scientific report 2019
Database coverage:
Medline ; Clarivate Analytics Master Journal List ; Emerging Sources Citation Index ; NCBI Molecular Biology Database ; PubMed Central ; Web of Science Core Collection
Click to display QR Code for this record

The record appears in these collections:
Document types > Articles > Journal Article
Public records
Publications database

 Record created 2019-02-28, last modified 2024-02-29



Rate this document:

Rate this document:
1
2
3
 
(Not yet reviewed)